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ABSTRACT 
Drotaverine Hydrochloride is effectively used in the treatment of management of spasticity, indicated in muscle pain as muscle relaxant. 
Drotaverine Hydrochloride approximately 95% bounds to plasma proteins and is metabolized by liver. In the present investigation, efforts 
were put to develop a sustained release floating matrix tablets of Drotaverine Hydrochloride. Gastro retentative dosage form will also greatly 
improve the pharmacotherapy of the stomach itself through local drug release leading to high drug concentrations at the gastr ic mucosa, which 
are sustained over a long period of time. Floating matrix tablets were prepared by direct compression method using sodium bicarbonate and 
citric acid as gas forming agents. HPMC K100M and Ethyl cellulose were used in the formula to retard drug release. Floating matrix tablets were 
evaluated for different quality attributes. In vitro drug release showed that polymer percentage is enough to extend the release of the drug for 
at least 12 hr. The dissolution curve shows that formulation FT-6 shows maximum drug release 79.37% at the end of 12 hours while FT-7 
shows least 46.33 %. 
 
Article Info: Received 24 March 2019;     Review Completed 03 May 2019;     Accepted 06 May 2019;     Available online 15 May 2019 
Cite this article as: 
Bhambar KV, Pande SD, Bhambar RS, Formulation and Evaluation of Floating Matrix Tablets of Drotaverine 
Hydrochloride, Journal of Drug Delivery and Therapeutics. 2019; 9(3):200-206    
http://dx.doi.org/10.22270/jddt.v9i3.2696                    
*Address for Correspondence:  
Kunal V Bhambar, MGV’s Samajshri Prashantdada Hiray College of Pharmacy, Malegaon, Nashik, Maharashtra, India   
 
   
INTRODUCTION 
Conventional drug therapy requires periodic doses of 
therapeutic agents. These agents are formulated to produce 
maximum stability, activity and bioavailability. For most 
drugs, conventional methods of drug administration are 
effective, but some drugs are unstable or toxic and have 
narrow therapeutic ranges. These problems were overcome 
by sustained release systems. Gastro retentative drug 
delivery is one of the promising approch to retard the drug 
release and to retain the dosage form in stomach region. It 
also improve drug absorption, because of increased GRT and 
more time spent by the dosage form at its absorption site. 
Absorption of the Drotaverine Hydrochloride is limited to 
upper part of the GI tract (stomach and upper part of small 
intestine) and bioavailability is 25-91%. Drotaverine 
Hydrochloride has a rapid and direct action on the smooth 
muscle. It acts to correct cyclic AMP and Ca imbalance at the 
spastic site, thereby relieving smooth muscle spasm and 
pain. Drotaverine Hydrochloride has a biological half-life of 
7 to 12 hours so it requires three-times a day dosing. Hence 
attempt was made to develop Drotaverine Hydrochloride 
floating matrix tablets to improve all characteristics. 7,8 
MATERIAL AND METHODS 
Drotaerine Hydrochloride was purchased from Swapnroop 
Drugs and Pharmaceuticals, Aurangabad, India. HPMC 
K100M, EC was procured from Molychem, Mumbai. All other 
reagent and materials were of analytical grade. 
Formulation of Drotaverine hydrochloride Floating 
Matrix Tablets.1  
The direct compression technique was followed to 
manufacture the Drotaverine hydrochloride tablets for all 
batches containing Drotaverine hydrochloride. Sodium 
bicarbonate was passed through # 36 sieves.  Magnesium 
stearate and Citric acid were passed through # 60 sieves. 
Weighed  amounts  of  drug  as  well  all  other ingredients  
were  transferred  into  polythene  bag  and  blended  for  10  
minutes.  The blend was compressed using 10-station rotary 
press using Round shaped punches. Punches measuring 11.2 
mm diameter were used for compression of the tablets. 
Formula for preparation of floating matrix tablets shown in 
table no-1 
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Table1: Formulation of Drotaverine hydrochloride floating Matrix tablets. 
Ingredients FT-1 
mg 
FT-2 
mg 
FT-3 
mg 
FT-4 
mg 
FT-5 
mg 
FT-6 
mg 
FT-7 
mg 
FT-8 
mg 
FT-9 
mg 
Drotaverine HCL 160 160 160 160 160 160 160 160 160 
HPMCK100M 60 50 50 40 60 40 60 40 50 
Ethyl cellulose 60 60 50 60 40 40 50 50 40 
Sodium bicarbonate 50 50 50 50 50 50 50 50 50 
Citric acid 25 25 25 25 25 25 25 25 25 
Magnesium 
Stearate 
5 5 5 5 5 5 5 5 5 
Total weight 360 350 340 340 340 320 350 330 330 
 
Organoleptic Properties 
The prepared tablets were evaluated visually for cracks, 
depressions, pinholes, colour and polish.  
Dimensions1  
Thickness of the tablets was measured using vernier 
calipers. 
Hardness test1  
The hardness was tested using Monsanto tester. “Hardness  
factor”,  the  average  of  the  six  determinations,  was  
determined  and  reported. 
Uniformity of weight1 
Twenty tablets were weighed individually. Average weight 
was calculated from the total weight of all tablets.  The 
individual weights were compared with the average weight.  
The  percentage  difference  in  the  weight  variation  should  
be  within  the  permissible  limits (7.5%). The percent 
deviation was calculated using the following formula.      
% Deviation =   Individual weight – Average weight    x 100 
                                                    Average weight            
Friability test1 
Roche friabilator was used to measure the friability of the 
tablets. Ten tablets were weighed collectively and placed in 
the chamber of the friabilator. It was rotated at a rate of 25 
rpm. In the friabilator, the tablets were exposed to rolling, 
resulting from free fall of tablets within the chamber of the 
friabilator. After  100  rotations  (4  minutes),  the  tablets  
were  taken  out  from  the friabilator  and  intact  tablets  
were  again  weighed  collectively.    Permitted friability limit 
is 1.0%. The percent friability was determined using the 
following formula                 
                                                      (W1 – W2)  
         Friability =                                                                x 100 
                                                  W1  
Where, W1 = weight of the tablets before test  
               W2 = weight of the tablets after test  
Content uniformity2 
Twenty tablets were selected randomly and average weight 
was calculated. Tablets were crushed in a  mortar  and  
accurately  average  weighed  amount  of  tablets  triturate  
was  taken  for  analysis.  Samples were transferred to 
different volumetric flasks and were diluted up to the mark 
using 0.1N hydrochloric acid. The content was shaken well  
and  kept  for  30  minutes  for  dissolving  the  drug  
completely. The mixtures were filtered and appropriate 
dilutions were made. The drug content in each tablet was 
estimated at λ max 240 nm against blank as reference.  
In vitro buoyancy studies3 
The tablets were placed in a 100 ml beaker containing 0.1  N 
hydrochloric acid. The time required for the tablet to rise to 
the surface and float was determined as floating lag time. 
The duration of time the dosage form constantly remained 
on the surface of medium was determined as the total 
floating time. 
Water uptake study (determination of swelling index) 3 
The swelling index of the tablets was determined in distilled 
water at room temperature. The water uptake study of the 
tablet was done using USP II dissolution apparatus. The 
medium used was distilled water, 900 ml, rotated at 100 
rpm. The medium was maintained at 37  0.50 C throughout 
the study. After every hour up to 12 hours, the tablets were 
withdrawn, blotted to remove excess water, and weighted. 
The swelling characteristics of the tablets were expressed in 
terms of water uptake (WU) as, 
% WU = Weight of the swollen tablet- Initial weight of the tablet 
x100 
                                           Initial weight of the tablet 
FT-IR Spectroscopy 
The FT-IR spectrum of formulation FT-6 was recorded using 
FTIR spectrophotometer (Shimadzu 84005) using Potassium 
Bromide pellet technique. Physical mixture of Drotaverine 
Hydrochloride and each polymer were scanned and 
recorded in the range of 4000-400 cm-1.  
Differential Scanning Calorimetry (DSC) 
DSC analysis of formulation FT-6 was performed using 
Shimadzu-Thermal Analyzer DSC 60 on 2-5mg samples. 
Samples were heated in an open aluminium pan at a rate of 
10°C/min conducted over a temperature range of 30 to 
300°C under a nitrogen flow of 2 bar pressure. 
In vitro dissolution study1 
In vitro drug release study of the samples was carried out 
using USP – type I dissolution apparatus (Basket type). The  
dissolution  medium,  900  ml  of  simulated  gastric fluid 
(without enzyme), was placed into the dissolution flask 
maintaining the  temperature  of  37    0.5 0C  and  rpm  of  
100.  One  Drotaverine  hydrochloride  matrix tablet  was  
placed  in  each  basket  of  the  dissolution  apparatus.  The 
apparatus was allowed to run for 12 hours.  Samples 
measuring 5 ml were withdrawn after every 1 hour up to 12 
hours manually. During sampling, samples were filtered.  
The fresh  dissolution  medium was  replaced  every  time  
with  the  same  quantity  of  the  sample.  Collected samples 
were analyzed at 240 nm using 0.1 N Hydrochloric Acid as 
blank.  The cumulative percentage drug release was 
calculated using PCP Disso v3 software. 
Kinetics of in-vitro drug release  
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To study the in-vitro drug release kinetics, data was applied 
to kinetic models such as zero order, first order, Higuchi, 
Hixson Crowell and Korsmeyer- Pappas. 
RESULT AND DISSCUSSION 
Organoleptic Properties: 
All the prepared matrix tablets were yellowish in color 
having smooth surface. The thickness of all the formulations 
was varies with drug: polymer ratio it ranges from 5.0-5.5 
mm. The weight variation test was carried out as per official 
method and the average percentage deviation of all the 
formulation was found to be less than 5 %. It was found that 
all batches shows percent drug content more than 95 %.The 
tablet hardness of all the formulations was determined and 
it was found in the range 6.9-7.1 kg/cm2. Another measure 
of tablet hardness was the friability. Compressed tablets that 
lose less than 1 % of their weight are generally considered 
acceptable. For all formulation tried here the weight loss 
was less than 1 % hence acceptable shown in table no 2. All 
the formulations FT-1 to FT-9 floats within one minute but 
FT-6 takes minimum time as it contains minimum amount of 
polymers.All the formulations FT-1 to FT-9 remain buoyant 
for more than20 hours shown in table no 4. Swelling index 
was performed for optimized formulation (FT-6) shown in 
fig. 1complete swelling of tablet takes place at the end of 8 
hours after that the weight of tablet decreases. The FTIR 
spectrum of FT-6 exhibited characteristic signals as shown 
in Table. The absorption bands shown by FT-6 are 
characteristic of the groups present in the molecular 
structure of Drotaverin Hydrochloride .The presence of 
absorption bands corresponding to the functional groups 
present in the structure of Drotaverin Hydrochloride and the 
absence of any well-defined unaccountable peaks is a 
confirmation of the purity of the formulation shown in table 
no.5 The DSC curve of Drotaverin Hydrochloride profiles a 
sharp endothermic peak at 216.77°C corresponding to its 
melting, and indicating its crystalline nature shown in fig 3. 
The DSC curve of FT-6 profiles a sharp endothermic peak at 
186.15°C corresponding to its melting, and indicating its 
crystalline nature. The shift in melting point was observed 
due to entrapment of drug within polymers. Drug release 
studies were made to determine whether the release of the 
drug is slow enough for at least 12 hr. The dissolution curve 
shows that formulation FT-6 shows maximum drug release 
79.37% at the end of 12 hours while FT-7 shows least 46.33 
% shown in table no.6 In order to determine the release 
model which best describes the pattern of drug release, the 
in-vitro release data were fitted to zero order, first order 
,Hixson crowell , krosmeyer peppas and diffusion controlled 
release mechanism according to simplified Higuchi model. 
The preference of a certain mechanism was based on the 
correlation coefficient r for the parameters studied, where 
the highest correlation coefficient is preferred for the 
selection of mechanism of release. The highest r value was 
obtained for krosmeyer peppas model, so swelling followed 
by diffusion and erosion  was the predominant release 
mechanism for floating matrix tablets. The value of release 
exponent n, obtained from Krosmeyer equation was greater 
than 0.5 for all nine formulations  FT 1-0.8473, FT2-0.8011, 
FT3-0.6763, FT4-0.7820, FT5-0.9046, FT6-0.8552, FT7-
0.8162, FT8-0.6851 and FT9-0.8515 indicate non -fickian 
transport. 
 
Table 2: Evaluation of tablets parameters 
Formul-
ation 
Code 
 
Thickness 
(mm) 
 
 
Hardness 
(Kg/cm2) 
 
         Weight variation 
Friability 
(%) 
Drug 
Content (%) Avg 
Wt (mg) 
Maximum % deviation 
(+Ve) (-Ve) 
FT1 5.30.10 6.90.15 360 +0.26 -0.38 0.210.08 99.750.29 
FT2 5.10.21 7.20.10 350 +0.85 -0.19 0.430.09 99.670.19 
FT3 5.20.35 6.60.25 340 +1.02 -0.67 0.280.05 99.450.40 
FT4 5.50.42 6.80.10 340 +0.89 -0.98 0.300.02 99.230.46 
FT5 5.20.21 7.20.20 340 +0.21 -1.68 0.470.05 99.700.26 
FT6 5.10.25 7.10.15 320 +1.32 -0.41 0.490.07 98.900.43 
FT7 5.00.32 7.30.08 350 +0.40 -0.62 0.510.05 99.630.21 
FT8 5.20.15 7.30.19 330 +0.83 -1.68 0.160.06 99.740.13 
FT9 5.30.20 7.10.07 330 +0.91 -1.56 0.210.02 99.440.36 
 
Table 3: Determination of buoyancy lag time 
Formulation code FT1 FT2 FT3 FT4 FT5 FT6 FT7 FT8 FT9 
Time (second) 34 50 30 38 32 25 37 36 33 
 
Table 4: Determination of duration of buoyancy: 
Formulation code FT1 FT2 FT3 FT4 FT5 FT6 FT7 FT8 FT9 
Time (Hours) 24 23 23 20 24 22 20 24 20 
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Figure 1: Swelling index of formulation (FT-6) 
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Figure 2: FT-IR of floating matrix tablet (FT-6) 
Table 5: Interpretation of FTIR spectrum of FT-6 
Peak observed (cm-1)  Interpretation 
2816.16,2874.03,2850.88 C-H stretching(aliphatic) 
3043.77 C-H stretching(aromatic) 
1602.90 C=C stretching 
1668.48 C=N stretching 
1037.74 C-O stretching 
 
100.00 200.00 300.00
Temp [C]
-15.00
-10.00
-5.00
0.00
mW
DSC
178.26x100COnset
192.87x100CEndset
186.15x100CPeak
-90.90x100J/gHeat
Sample Name: FT-3
[Temp Program]
Start Temp 35.0
Temp Rate Hold Temp Hold Time Gas
[C/min ] [  C   ] [  min  ]
10.00 300.0 0 2
214.84x100COnset
219.10x100CEndset
216.77x100CPeak
-112.16 x100J/gHeat
Sample Name: DRT pure
 
Figure 3: DSC Overlay of FT-6 and Drotaverine Hydrochloride 
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Table 6: Cumulative % drug released profile of Dvcl floating matrix tablets. 
Time 
(Hours) 
Cumulative % release (mean  S.D.) 
Formulation code 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 7.47 
 0.69 
7.99 
0.32 
11.68 
0.36 
10.54 
0.80 
5.25 
0.52 
9.82 
0.20 
6.25 
0.32 
14.03 
0.49 
8.36 
2.83 
2 13.55 
0.85 
13.72 
0.51 
16.50 
0.34 
16.69 
1.02 
10.47 
0.59 
16.93 
3.20 
10.11 
0.34 
17.57 
0.28 
13.82 
2.31 
3 18.72 
0.75 
19.65 
0.87 
17.25 
0.34 
23.75 
1.07 
12.42 
0.89 
24.67 
0.51 
13.97 
0.37 
25.36 
0.52 
21.03 
1.49 
4 25.86 
0.97 
25.22 
0.49 
20.41 
0.30 
29.49 
2.70 
18.17 
1.48 
32.81 
0.22 
21.01 
0.23 
33.25 
0.56 
26.72 
1.63 
5 28.70 
1.47 
29.79 
0.22 
26.15 
0.41 
36.90 
2.08 
20.99 
2.61 
39.54 
0.53 
21.76 
0.56 
38.41 
1.12 
31.99 
1.17 
6 35.47 
3.96 
34.31 
0.60 
31.82 
0.51 
42.09 
1.20 
25.39 
4.33 
45.89 
0.48 
26.42 
0.67 
43.54 
1.06 
37.64 
1.43 
7 39.70 
0.49 
37.57 
0.39 
35.84 
0.53 
46.09 
0.92 
29.15 
0.69 
52.50 
1.17 
29.94 
0.39 
47.67 
0.99 
42.51 
0.63 
8 44.81 
1.14 
39.32 
0.37 
38.25 
0.51 
52.81 
1.07 
34.41 
0.93 
58.28 
0.54 
33.34 
0.59 
50.65 
0.41 
47.96 
1.94 
9 48.20 
0.68 
46.73 
0.34 
43.71 
1.20 
56.74 
1.11 
38.50 
0.43 
63.69 
0.42 
36.35 
0.39 
58.20 
2.20 
52.75 
1.04 
10 52.64 
0.36 
49.59 
0.40 
50.31 
1.03 
61.99 
0.87 
41.47 
1.36 
68.58 
0.58 
39.11 
0.41 
61.09 
1.80 
57.42 
0.44 
11 56.57 
0.68 
57.70 
0.26 
52.54 
0.63 
66.20 
0.69 
46.78 
0.48 
75.74 
2.01 
42.45 
0.26 
66.38 
3.13 
62.39 
0.36 
12 61.14 
 0.69 
59.03 
0.32 
60.18 
0.36 
70.34 
0.80 
49.20 
0.52 
79.37 
0.20 
46.33 
0.32 
69.31 
0.49 
67.82 
2.83 
 
 
Figure 4: Comparative Dissolution profile of floating matrix tablets 
Table 7: Kinetic treatment of prepared Drotaverine HCL floating matrix tablets. 
 
Formulati
on Code 
                              Coefficient of determination (r2) 
 
  
Korsmeyer plot  
n (release exponent)  Zero 
order 
 First 
order 
 Higuchi   
square root  
Hixson Crowell 
Cube Root 
Korsmeyer  
plot 
FT1 0.9914 0.9914 0.9585 0.9914 0.9993 0.8473 
FT2 0.9875 0.9927 0.9603 0.9949 0.9985 0.8011 
FT3 0.9856 0.9848 0.9509 0.9892 0.9751  0.6763 
FT4 0.9855 0.9855 0.9671 0.9855 0.9992 0.7820 
FT5 0.9983 0.9983 0.9369 0.9983 0.9974 0.9046 
FT6 0.9919 0.9919 0.9579 0.9919 0.9994 0.8552 
FT7 0.9887 0.9887 0.9608 0.9887 0.9974 0.8162 
FT8 0.9694 0.9695 0.9786 0.9694 0.9937 0.6851 
FT9 0.9944 0.9944 0.9545 0.9944 0.9995 0.8515 
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Figure 5: Combined zero order graphs of Floating Matrix Tablets 
 
Figure 6: Combined first order graphs of Floating Matrix Tablets 
 
Figure 7: Combined Higuchi graph of Floating Matrix Tablets 
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Figure 8: Combined Hixson Crowell graph of Floating Matrix Tablets 
 
Figure 9: Combined Korsmeyer Peppas graph of Floating Matrix  Tablets 
CONCLUSION 
Floating lag time was within 1 minute and total floating time 
was  more than 20 hours for all the developed formulations. 
For floating matrix tablets, the formulation FT-6 shows 
highest drug release as containing minimum amount of 
polymers and FT-7 shows lowest drug release. For floating 
matrix tablets, according to ‘r’ value, Korsmeyer-Peppas 
model was the best suited for drug release i.e. diffusion 
phenomenon but n value obtained from Korsmeyer-Peppas 
equation was within 0.5 <n> 1.0 which indicates anamolous 
releases. So the actual mechanism of drug release was 
swelling or rearrangement of polymers followed by diffusion 
and erosion.    
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